HOTH THERAPEUTICS, INC. Today’s news comes on the heels of the Company’s announcement of the successful completion of its first small animal safety and immunogenicity study assessing the effect of novel vaccine Halovax™ against COVID-19. The vaccine construct was completed with positive response to selected COVID-19 peptides in conjunction with the self-assembling vaccine prototype. The study demonstrates that selection algorithm for immunogenic peptides is functioning appropriately.
HaloVax is being developed in conjunction with
The company’s vaccines are built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which have used adjuvants such as alum. The second portion of the vaccine consists of peptides derived from the target of the vaccine – which can be a virus or a cancer patient’s tumor. These are bound to the heat shock protein via Avidin and Biotin. This enables rapid iteration and up-to-date data informed changes in the peptide sequences to enable swift production of the vaccine.
“We are pleased to have executed a manufacturing agreement with an international contract manufacturer for our vaccine portfolio. This initiative builds atop our recent operational momentum, including our recently announced successful preclinical testing of our COVID-19 vaccine candidate. We are now actively moving toward starting clinical trials in humans with the goal of bringing to market proven and effective vaccines to help treat a range of conditions, including various cancers and COVID-19,” said
About
About HaloVax™, LLC
About
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron’s current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the
Investor Contacts:
President
646-335-5923
mduffy@luciuspartnersllc.com
Investor Relations
678-570-6791
jwassad@bellsouth.net
2020 GlobeNewswire, Inc., source
